uridine triacetate: A uridine prodrug that is used in the treatment of hereditary orotic aciduria. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
uridine triacetate : An acetate ester that is uracil in which the three hydroxy hydrogens are replaced by acetate group. A prodrug for uridine, it is used for the treatment of hereditary orotic aciduria and for management of fluorouracil toxicity. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 20058 |
| CHEMBL ID | 2107381 |
| CHEBI ID | 90914 |
| SCHEMBL ID | 871011 |
| MeSH ID | M0277544 |
| Synonym |
|---|
| 2',3',5'-tri-o-acetyluridine, >=98% |
| 2',3',5'-tri-o-acetyluridine |
| uridine 2',3',5'-triacetate |
| 4105-38-8 |
| [(2r,3r,4r,5r)-3,4-diacetyloxy-5-(2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl acetate |
| vistogard (tn) |
| xuriden (tn) |
| D09985 |
| uridine triacetate (usan/inn) |
| uridine 2',3',5'-triacetate;2',3',5'-triacetyluridine |
| A825419 |
| AKOS015964563 |
| c15h18n2o9 |
| xuriden |
| pn401 |
| rg 2133 |
| unii-2wp61f175m |
| vistogard |
| 2wp61f175m , |
| pn 401 |
| uridine triacetate [usan:inn] |
| pn-401 |
| triacetyluridine |
| einecs 223-881-5 |
| vistonuridine |
| tri-o-acetyluridine |
| rg2133 |
| rg-2133 |
| uridine triacetate |
| uridine triacetate [orange book] |
| uridine triacetate [who-dd] |
| uridine triacetate [inn] |
| uridine triacetate [mi] |
| uridine triacetate [usan] |
| CHEMBL2107381 |
| S6484 |
| SCHEMBL871011 |
| smr004701034 |
| MLS006009982 |
| 2 inverted exclamation mark ,3 inverted exclamation mark ,5 inverted exclamation mark -triacetyluridine |
| SY004945 |
| mfcd00023795 |
| J-700012 |
| CHEBI:90914 |
| AUFUWRKPQLGTGF-FMKGYKFTSA-N |
| (2r,3r,4r,5r)-2-(acetoxymethyl)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2h)-yl)tetrahydrofuran-3,4-diyl diacetate |
| DB09144 |
| CS-D1799 |
| HY-14905 |
| Q22075857 |
| uridinetriacetate |
| uridine-triacetate |
| DTXSID40961409 |
| uridine, 2,3,5-triacetate |
| nsc788948 |
| nsc-788948 |
| EN300-7359679 |
| [(2r,3r,4r,5r)-3,4-bis(acetyloxy)-5-(2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)oxolan-2-yl]methyl acetate |
| Excerpt | Reference | Relevance |
|---|---|---|
| " The present results suggest that the BBBA plus TAU combination can provide a better substitute for the massive doses of uridine required to achieve the high levels of uridine necessary to rescue or protect from FUra host toxicities without the toxic side-effects associated with such doses of uridine." | ( Modulation of 5-fluorouracil host toxicity by 5-(benzyloxybenzyl)barbituric acid acyclonucleoside, a uridine phosphorylase inhibitor, and 2',3',5'-tri-O-acetyluridine, a prodrug of uridine. Al Safarjalani, ON; Ashour, OM; el Kouni, MH; Naguib, FN; Panzica, RP, 2000) | 0.31 |
| "5 weeks (range 3-4 weeks), indicating that Vistogard might be able to delay 5-FU toxicity despite higher doses than standard bolus dose of 5-FU used in gastrointestinal malignancies and the appearance of a potentially less toxic adverse effect of 5-FU at an unusual site (cutaneous) in one patient." | ( Benefit of uridine triacetate (Vistogard) in rescuing severe 5-fluorouracil toxicity in patients with dihydropyrimidine dehydrogenase (DPYD) deficiency. Diasio, RB; Saif, MW, 2016) | 0.43 |
| " Uridine triacetate delivers high concentrations of uridine, which competes with toxic 5-FU metabolites." | ( Emergency use of uridine triacetate for the prevention and treatment of life-threatening 5-fluorouracil and capecitabine toxicity. Bamat, MK; Cartwright, TH; El-Rayes, BF; Fakih, MG; King, TR; Ma, WW; Posey, JA; Saif, MW; von Borstel, RW, 2017) | 0.46 |
| " Adverse reactions in patients receiving uridine triacetate included vomiting (8." | ( Emergency use of uridine triacetate for the prevention and treatment of life-threatening 5-fluorouracil and capecitabine toxicity. Bamat, MK; Cartwright, TH; El-Rayes, BF; Fakih, MG; King, TR; Ma, WW; Posey, JA; Saif, MW; von Borstel, RW, 2017) | 0.46 |
| "In these studies, uridine triacetate was a safe and effective lifesaving antidote for capecitabine and 5-FU overexposure, and it facilitated the rapid resumption of chemotherapy." | ( Emergency use of uridine triacetate for the prevention and treatment of life-threatening 5-fluorouracil and capecitabine toxicity. Bamat, MK; Cartwright, TH; El-Rayes, BF; Fakih, MG; King, TR; Ma, WW; Posey, JA; Saif, MW; von Borstel, RW, 2017) | 0.46 |
| " This review summarizes the current state of knowledge of FIC with special regard to proposed pathogenetic models (coronary vasospasm, endothelium and cardiomyocytes damage, toxic metabolites, dihydropyrimidine dehydrogenase deficiency); risk and predictive factors; efficacy and usefulness in detection of laboratory markers, electrocardiographic changes and cardiac imaging; and specific treatment, including a novel agent, uridine triacetate." | ( Fluoropyrimidine-induced cardiotoxicity. Aglietta, M; Bonzano, A; Cagnazzo, C; Depetris, I; Filippi, R; Leone, F; Marino, D, 2018) | 0.48 |
| Role | Description |
|---|---|
| prodrug | A compound that, on administration, must undergo chemical conversion by metabolic processes before becoming the pharmacologically active drug for which it is a prodrug. |
| neuroprotective agent | Any compound that can be used for the treatment of neurodegenerative disorders. |
| orphan drug | Any drug that has been developed specifically for treatment of a rare medical condition, the condition itself being known as an orphan disease. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| uridines | |
| acetate ester | Any carboxylic ester where the carboxylic acid component is acetic acid. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID140061 | Tested for PB (pentobarbital)-induced sleep effect expressed as percent control of sleeping time at a dosage (icv) of 2.0 uM concentration | 1987 | Journal of medicinal chemistry, Dec, Volume: 30, Issue:12 | N-substituted oxopyrimidines and nucleosides: structure-activity relationship for hypnotic activity as central nervous system depressant. |
| AID123974 | Hypnotic activity in ddN strain mice by the iv administration of 0.5 mmol/kg; No activity. | 1987 | Journal of medicinal chemistry, Dec, Volume: 30, Issue:12 | N-substituted oxopyrimidines and nucleosides: structure-activity relationship for hypnotic activity as central nervous system depressant. |
| AID123963 | Hypnotic activity expressed as sleeping time was determined in ddN strain mice by the icv administration of 2.0 uMol/mouse of the compound | 1987 | Journal of medicinal chemistry, Dec, Volume: 30, Issue:12 | N-substituted oxopyrimidines and nucleosides: structure-activity relationship for hypnotic activity as central nervous system depressant. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (2.63) | 18.7374 |
| 1990's | 1 (2.63) | 18.2507 |
| 2000's | 11 (28.95) | 29.6817 |
| 2010's | 20 (52.63) | 24.3611 |
| 2020's | 5 (13.16) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (19.39) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 5 (12.82%) | 5.53% |
| Reviews | 6 (15.38%) | 6.00% |
| Case Studies | 10 (25.64%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 18 (46.15%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||